Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells

被引：14

作者：

Chen, Yilin ^{[1
]}

Zou, Jing ^{[1
]}

Cheng, Fanjun ^{[1
]}

Li, Weiming ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

chronic myeloid leukemia; tyrosine kinase inhibitors; leukemia stem cells; discontinuation; treatment-free remission; CHRONIC MYELOGENOUS LEUKEMIA; MAJOR MOLECULAR RESPONSE; TYROSINE KINASE INHIBITORS; MINIMAL RESIDUAL DISEASE; BCR-ABL; CML STEM; IMATINIB DISCONTINUATION; THERAPEUTIC TARGET; IN-VITRO; ENHANCES ELIMINATION;

D O I：

10.3389/fonc.2021.769730

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The therapeutic landscape for chronic myeloid leukemia (CML) has improved significantly with the approval of tyrosine kinase inhibitors (TKIs) for therapeutic use. Most patients with optimal responses to TKIs can have a normal life expectancy. Treatment-free remission (TFR) after discontinuing TKI has increasingly become a new goal for CML treatment. However, TKI only "control" CML, and relapse after discontinuation has become a key factor hindering patient access to attempt TFR. In this study, we reviewed studies on TKI discontinuation, including both first and second-generation TKI. We also reviewed predictors of relapse, new monitoring methods, and strategies targeting leukemic stem cells.</p>

引用

页数：16

共 169 条

[1] SIRT1 regulates metabolism and leukemogenic potential in CML stem cells [J].

Abraham, Ajay ;

Qiu, Shaowei ;

Chacko, Balu K. ;

Li, Hui ;

Paterson, Andrew ;

He, Jianbo ;

Agarwal, Puneet ;

Shah, Mansi ;

Welner, Robert ;

Darley-Usmar, Victor M. ;

Bhatia, Ravi .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (07) :2685-2701

[2] Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database [J].

Abruzzese, Elisabetta ;

Turkina, Anna G. ;

Apperley, Jane F. ;

Bondanini, Francesco ;

de Fabritiis, Paolo ;

Kim, Dong-Wook ;

Dyagil, Iryna ;

Ganeva, Penka ;

Garcia-Gutierrez, Valentin ;

Kazakbaeva, Khamida ;

Klamova, Hana ;

Kotlyarchuk, Konstantin ;

Mauro, Michael J. ;

Milojkovic, Dragana ;

Moriaghi, Beatriz ;

Meliktesyan, Karen ;

Nicolini, Franck E. ;

Polushkina, Evgenia ;

Rea, Delphine ;

Rousselot, Philippe ;

Shacham, Adi ;

Shmakov, Roman ;

Trawinska, Malgorzata Monika ;

Chelysheva, Ekaterina Yu. .

BLOOD, 2019, 134

[3] TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling [J].

Agarwal, Puneet ;

Li, Hui ;

Choi, Kwangmin ;

Hueneman, Kathleen ;

He, Jianbo ;

Welner, Robert S. ;

Starczynowski, Daniel T. ;

Bhatia, Ravi .

CELL REPORTS, 2021, 36 (02)

[4] Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells [J].

Agarwal, Puneet ;

Isringhausen, Stephan ;

Li, Hui ;

Paterson, Andrew J. ;

He, Jianbo ;

Gomariz, Alvaro ;

Nagasawa, Takashi ;

Nombela-Arrieta, Cesar ;

Bhatia, Ravi .

CELL STEM CELL, 2019, 24 (05) :769-+

[5] IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models [J].

Agerstam, Helena ;

Hansen, Nils ;

von Palffy, Sofia ;

Sanden, Carl ;

Reckzeh, Kristian ;

Karlsson, Christine ;

Lilljebjorn, Henrik ;

Landberg, Niklas ;

Askmyr, Maria ;

Hogberg, Carl ;

Rissler, Marianne ;

Porkka, Kimmo ;

Wadenvik, Hans ;

Mustjoki, Satu ;

Richter, Johan ;

Jaras, Marcus ;

Fioretos, Thoas .

BLOOD, 2016, 128 (23) :2683-2693

[6] The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission [J].

Andrews, Claire ;

Lipton, Jeffrey .

LEUKEMIA & LYMPHOMA, 2019, 60 (13) :3099-3101

[7] Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors [J].

Angstreich, GR ;

Matsui, W ;

Huff, CA ;

Vala, MS ;

Barber, J ;

Hawkins, AL ;

Griffin, CA ;

Smith, GBD ;

Jones, RJ .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) :373-381

[8] Chronic myeloid leukaemia [J].

Apperley, Jane F. .

LANCET, 2015, 385 (9976) :1447-1459

[9] Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia A Nonrandomized Clinical Trial [J].

Atallah, Ehab ;

Schiffer, Charles A. ;

Radich, Jerald P. ;

Weinfurt, Kevin P. ;

Zhang, Mei-Jie ;

Pinilla-Ibarz, Javier ;

Kota, Vamsi ;

Larson, Richard A. ;

Moore, Joseph O. ;

Mauro, Michael J. ;

Deininger, Michael W. N. ;

Thompson, James E. ;

Oehler, Vivian G. ;

Wadleigh, Martha ;

Shah, Neil P. ;

Ritchie, Ellen K. ;

Silver, Richard T. ;

Cortes, Jorge ;

Lin, Li ;

Visotcky, Alexis ;

Baim, Arielle ;

Harrell, Jill ;

Helton, Bret ;

Horowitz, Mary ;

Flynn, Kathryn E. .

JAMA ONCOLOGY, 2021, 7 (01) :42-50

[10] The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial [J].

Austin, Gemma M. ;

Knight, Katy ;

Bell, Joanne ;

Carter, Anthony ;

Heartin, Earnest ;

Watson, David ;

Foroni, Letizia ;

Christmas, Stephen E. ;

Polydoros, Fotios ;

Clark, Richard E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (04) :791-793

← 1 2 3 4 5 6 7 8 9 10 →